Fertin
  • Delivery systems
    • Zapliq®
    • Compressed gum
    • Extruded gum
    • Lozenge
    • Pouch powder
    • Custom delivery systems and co-development
  • Application areas
    • Nicotine
    • Cannabinoids
    • Vitamins and dietary supplements
    • Oral care
    • Energy management
    • Pain management
    • Allergy
    • Cough and cold
    • Gastrointestinal
    • Sleep and relaxation
  • Services
    • Research and development
    • Manufacturing and packaging
    • Sensory optimisation
    • Regulatory and compliance
    • Quality control and assurance
    • Intellectual property
  • News & insights
    • News
    • Insights
  • Sustainability
  • About
    • Fertin Pharma Group
    • Fertin India
    • NordicCan
    • Tab Labs
  • Careers
  • Contact
  • Search
  • Account
  • Delivery systems
    • Zapliq®
    • Compressed gum
    • Extruded gum
    • Lozenge
    • Pouch powder
    • Custom delivery systems and co-development
  • Application areas
    • Nicotine
    • Cannabinoids
    • Vitamins and dietary supplements
    • Oral care
    • Energy management
    • Pain management
    • Allergy
    • Cough and cold
    • Gastrointestinal
    • Sleep and relaxation
  • Services
    • Research and development
    • Manufacturing and packaging
    • Sensory optimisation
    • Regulatory and compliance
    • Quality control and assurance
    • Intellectual property
  • News & insights
    • News
    • Insights
  • Sustainability
  • About
    • Fertin Pharma Group
    • Fertin India
    • NordicCan
    • Tab Labs
  • Careers
  • Contact
  • Search
  • Account
Fertin
2020-04-24

Nicotine giant expects progress in 2020 – products successful during the corona crisis

Nicotine giant expects progress in 2020 – products successful during the corona crisis

2020-04-24

After a decline in earnings in 2018, Fertin experienced growth in 2019 and is optimistic despite the corona crisis. The top line has jumped from DKK 813 million in 2018 to DKK 882 million DKK in 2019.

With CEO Søren Birn in the lead, the company has cut its staff from 674 to 569 employees since last year while handling a growing product demand.

Fertin continues to transition from being a nicotine chewing gum manufacturer to investing in several product categories and has worked diligently on diversifying the business. This now bears fruit and Fertin expects the result for 2020 to surpass 2019.

“We can see that especially our smoking cessation products have a tailwind during the corona crisis. The pandemic has highlighted that smoking may not be the cleverest. Of course, we are favored by this commercially,” says Søren Birn.

Read full article (in Danish) here: https://borsen.dk/nyheder/virksomheder/nikotinkaempe-forventer-fremgang-i-2020

 

Share
Archive
  • 2021
  • 2020
  • 2019
Deliver active and functional ingredients to your consumer in a pleasurable and effective way
Dandyvej 19, DK-7100 Vejle, Denmark
+45 7215 1300  |  fertin@fertin.com
Follow us
How can we help?
Discuss your next product with our experts today
Dandyvej 19, DK-7100 Vejle, Denmark
+45 7215 1300  |  fertin@fertin.com
Fertin Pharma 2019. All Rights Reserved.
Disclaimer | Privacy Policy | Cookie Policy | Food Safety
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.